AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Kite pharma employees3/1/2024 ![]() To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. This story was originally published on BioPharma Dive. While the agency is considering “regulatory action,” it said “the overall benefits of these products continue to outweigh their potential risks for their approved uses.” Job Description Cell Therapy Specialist I Kite is seeking a highly motivated individual with cell culture experience to work on innovative T cell therapy for cancer treatment. News of the layoffs comes as the Food and Drug Administration is investigating reports of T cell malignancies in people who received CAR-T therapies like Yescarta. For Current Kite Pharma Employees and Contractors: Please log onto your Internal Career Site to apply for this job. “While our business is performing well and we are making a meaningful impact for patients eligible for CAR T therapy, we believe there is a great deal of opportunity to continue to drive the adoption of our therapies,” the company said in its statement to BioPharma Dive. Perettie, previously CEO of Roche’s Foundation Medicine, took charge of Kite in May after Christi Shaw stepped down from the role. While sales were initially slow, they’ve steadily risen and totaled nearly $500 million in the third quarter between the two therapies. Both cost hundreds of thousands of dollars per patient, and involve a complex and lengthy treatment process. Yescarta was the unit’s first approved, and recently received an expanded clearance in the U.S. Kite is a leading producer of CAR-T cell therapies, which involve the engineering of a patients’ own immune cells to better fight cancer. ![]() The unit, which was eventually set up as a standalone division, formed the foundation of the California biotechnology company’s push into oncology, now a major part of its business. 40 Jobs 32 Q&A Interviews 4 Photos Want to work here View jobs Kite Pharma Employee Reviews Review this company Job Title All Location United States 61 reviews Ratings by category 3.3 Work-Life Balance 4. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you have. Gilead acquired Kite Pharma in 2017 for nearly $12 billion in a major bet on cell therapy. The average salary for Cell Therapy Specialist at companies like KITE PHARMA in the United States is 79,616 as of October 25, 2023, but the range typically falls between 72,993 and 86,239. More than 4,000 people work at Kite, which developed and sells the CAR-T treatments Yescarta and Tecartus for certain leukemias and lymphomas. Fierce Pharma earlier reported the news, citing a letter from Kite Pharma head Cindy Perettie that outlined a “refreshed business strategy.” Gilead Sciences is laying off about 7% of employees at cell therapy unit Kite Pharma in a restructuring it said is meant to better align the division’s organization with areas of future growth.Ībout 90 new positions will be created as part of the changes, a spokesperson for Kite Pharma confirmed to BioPharma Dive, meaning the net impact is equivalent to around 5% of Kite’s workforce.
0 Comments
Read More
Leave a Reply. |